Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Wallentin, Lars; Eriksson, Niclas; Olszowka, M; Grammer, Tanja B.; Hagström, Emil; Held, Claes; Kleber, Marcus E.; Köenig, Wolfgang; März, Winfried; Stewart, Ralph; White, Harvey D.; Åberg, Mikael; Siegbahn, Agneta

doi:10.1371/journal.pmed.1003513

Cited by 97 publications

(63 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that compared to other biomarkers such as natriuretic peptides and troponins (Aimo et al, 2019;Berg, Ruff, & Morrow, 2021;Cediel et al, 2021;Perrone et al, 2020;Wallentin et al, 2021), sST2 concentration is independent on the age, renal function or body mass index (Dieplinger et al, 2009). These findings were confirmed in our study as well.…”

Section: Discussionsupporting

confidence: 88%

Prognostic value of serum soluble ST2 in professional athletes (Valor pronóstico de ST2 soluble en suero en deportistas profesionales)

Baurzhan¹,

Berkinbayev²,

Abzaliyev³

et al. 2021

Retos

View full text Add to dashboard Cite

Background: The predictive value of serum soluble ST2 (sST2) biomarker for diagnostics of cardiovascular pathologies is still poorly understood as well as the role of psychological stress on the risk of heart disease. Aim: This study aimed at determining the diagnostic significance of the sST2 level in athletes involved in speed-strength sports. In addition, stress as a risk factor for the development of cardiovascular pathology was assessed and analysed as well. Methods: A prospective study on Greco-Roman wrestlers was carried out at the Centre for Sports Medicine and Rehabilitation (Almaty, Republic of Kazakhstan). All participants (n = 30) were males aged 20 to 34 years. The control group consisted of volunteers (VO) (n = 30). Anthropometric and hemodynamic parameters of athletes were studied along with electrocardiography (ECG) and ECG tests. The sST2 level was determined before (BT) and immediately after (AT) training. The stress level was determined using The Perceived Stress Scale-10 (PSS-10). Results: The average age of the athletes was 26.57 ± 3.6 years. The total training experience was 14.57 ± 4.02 years. According to the ECG data, minor deviations from the norm (13.3%) and an abnormal ECG (33.3%) were identified. Echo-CG data showed "moderate" and "pronounced changes" in 23.3% and 53.3% of cases, respectively. The sST2 level of VO (337.1 ± 61.8 pg / mL) was lower than that of BT (548.1 ± 32.6 pg / mL) (p ≤ 0.001). The sST2 level of AT, it was significantly higher (830.01 ± 71.6 pg / mL) than BT (p ≤ 0.001). The average and high level of stress among athletes was in 43.3% and 56.7% of cases, respectively. Stress increased the likelihood of developing distinctly abnormal ECG (OR = 1.06, 95% CI 1.01–1.08; p = 0.02). The stress level showed a positive correlation with the sST2 level (r = 0.752, p = 0.01). The sST2 concentration and categorical echocardiography data demonstrated a dependent positive correlation (r = 0.6, p = 0.01). Conclusions: Athletes' sST2 levels exceeded thresholds both before and after training. Moreover, the relationship between an increase in sST2 levels and abnormal ECG abnormalities and a high level of stress in athletes was determined. sST2 concentration was associated with cardio-pulmonary stress triggered by the cumulative exercise dose as well as with lifelong psychological stress. Our findings indicate that the elevated sST2 concentrations in athletes could be used as the predictive value. However, clinical relevance and results validity require further intensive studies. Resumen. Antecedentes: El valor predictivo del biomarcador ST2 soluble en suero (sST2) en la enfermedad cardiovascular aún no se conoce bien, así como el papel del estrés psicológico en el riesgo de enfermedad cardiovascular. Objetivos: Este estudio tuvo como objetivo determinar la importancia diagnóstica del nivel de sST2 en atletas involucrados en deportes de velocidad-fuerza. Además, también se evaluó y analizó el estrés como factor de riesgo para el desarrollo de patología cardiovascular. Métodos: Se llevó a cabo un estudio prospectivo sobre luchadores grecorromanos en el Centro de Medicina y Rehabilitación del Deporte (Almaty, República de Kazajstán). Todos los participantes (n = 30) eran hombres de entre 20 y 34 años. El grupo de control estaba formado por voluntarios (VO) (n = 30). Se estudiaron los parámetros antropométricos y hemodinámicos de los atletas junto con las pruebas de electrocardiografía (ECG). El nivel de sST2 se determinó antes (BT) e inmediatamente después (AT) del entrenamiento. El nivel de estrés se determinó utilizando la Escala de Estrés Percibido-10 (PSS-10). Resultados: La edad promedio de los deportistas fue de 26,57 ± 3,6 años. La experiencia de formación total fue de 14,57 ± 4,02 años. Según los datos del ECG, se identificaron desviaciones menores de la norma (13,3%) y un ECG anormal (33,3%). Los datos de Echo-CG mostraron cambios "moderados" y "pronunciados" en el 23,3% y el 53,3% de los casos, respectivamente. El nivel de sST2 del grupo VO (337,1 ± 61,8 pg / mL) fue menor que el de BT (548,1 ± 32,6 pg / mL) (p ≤ 0,001),). El nivel de sST2 en AT fue significativamente mayor (830.01 ± 71.6 pg / mL) que en BT (p ≤ 0.001). El nivel medio y alto de estrés entre los deportistas fue del 43,3% y el 56,7% de los casos, respectivamente. El estrés aumentó la probabilidad de desarrollar un ECG claramente anormal (OR = 1,06; IC del 95%: 1,01-1,08; p = 0,02). El nivel de estrés mostró una correlación positiva con el nivel de sST2 (r = 0,752, p = 0,01). La concentración de sST2 y los datos de la ecocardiografía categórica demostraron una correlación positiva dependiente (r = 0,6, p = 0,01). Conclusión: Los niveles de sST2 de los atletas excedieron los umbrales tanto antes como después del entrenamiento. Además, se determinó la relación entre un aumento en los niveles de sST2 y anomalías anormales del ECG y un alto nivel de estrés en los atletas. La concentración de sST2 se asoció con el estrés cardiopulmonar desencadenado por la dosis acumulativa de ejercicio, así como con el estrés psicológico de por vida. Nuestros hallazgos indican que las concentraciones elevadas de sST2 en los atletas pueden usarse como valor predictivo. Sin embargo, se requieren más estudios.

show abstract

Section: Discussionsupporting

confidence: 88%

Prognostic value of serum soluble ST2 in professional athletes (Valor pronóstico de ST2 soluble en suero en deportistas profesionales)

Baurzhan¹,

Berkinbayev²,

Abzaliyev³

et al. 2021

Retos

View full text Add to dashboard Cite

show abstract

“…Likewise, interesting observations have been reported for MR-pro ADM regarding catheter ablation, infectious endocarditis, and transcatheter aortic valve replacement [ 101 – 104 ]. Wallentin et al performed a comparative analysis of the importance of biomarkers in chronic coronary heart disease and reported that NT-pro-BNP, troponin-T, and BNP demonstrate high importance, while AM remains less important [ 105 ]. Current guidelines recommend only BNP and/or NT-pro-BNP as markers for HF management [ 106 ].…”

Section: Plasma Levels Of Ammentioning

confidence: 99%

Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases

Kita

Kïtamura

2022

Hypertens Res

View full text Add to dashboard Cite

Adrenomedullin (AM) is a vasodilative peptide with various physiological functions, including the maintenance of vascular tone and endothelial barrier function. AM levels are markedly increased during severe inflammation, such as that associated with sepsis; thus, AM is expected to be a useful clinical marker and therapeutic agent for inflammation. However, as the increase in AM levels in cardiovascular diseases (CVDs) is relatively low compared to that in infectious diseases, the value of AM as a marker of CVDs seems to be less important. Limitations pertaining to the administrative route and short half-life of AM in the bloodstream (<30 min) restrict the therapeutic applications of AM for CVDs. In early human studies, various applications of AM for CVDs were attempted, including for heart failure, myocardial infarction, pulmonary hypertension, and peripheral artery disease; however, none achieved success. We have developed AM as a therapeutic agent for inflammatory bowel disease in which the vasodilatory effect of AM is minimized. A clinical trial evaluating this AM formulation for acute cerebral infarction is ongoing. We have also developed AM derivatives that exhibit a longer half-life and less vasodilative activity. These AM derivatives can be administered by subcutaneous injection at long-term intervals. Accordingly, these derivatives will reduce the inconvenience in use compared to that for native AM and expand the possible applications of AM for treating CVDs. In this review, we present the latest translational status of AM and its derivatives.

show abstract

“…, cervical and lymphoma), in type 2 diabetes mellitus, and in coronary heart disease, suggesting an association between this biomarker and the presence of chronic disease in general[ 18 ]. CA 125, also known as mucin 16, has the same drawback, being most frequently used in the diagnosis of ovarian cancer[ 19 ], and altered CA 125 concentrations have been observed in a wide range of diseases, including heart failure[ 20 ], pulmonary disorders[ 21 ], deep endometriosis[ 22 ], and extrapulmonary tuberculosis[ 23 ].…”

Section: Carbohydrate Antigen 19-9 Other Carbohydrate Markers and Carcinoembryonic Antigenmentioning

confidence: 99%

Liquid biopsy approach to pancreatic cancer

Perales

Torres

Jiménez-Luna

et al. 2021

WJGO

View full text Add to dashboard Cite

Pancreatic cancer (PC) continues to pose a major clinical challenge. There has been little improvement in patient survival over the past few decades, and it is projected to become the second leading cause of cancer mortality by 2030. The dismal 5-year survival rate of less than 10% after the diagnosis is attributable to the lack of early symptoms, the absence of specific biomarkers for an early diagnosis, and the inadequacy of available chemotherapies. Most patients are diagnosed when the disease has already metastasized and cannot be treated. Cancer interception is vital, actively intervening in the malignization process before the development of a full-blown advanced tumor. An early diagnosis of PC has a dramatic impact on the survival of patients, and improved techniques are urgently needed to detect and evaluate this disease at an early stage. It is difficult to obtain tissue biopsies from the pancreas due to its anatomical position; however, liquid biopsies are readily available and can provide useful information for the diagnosis, prognosis, stratification, and follow-up of patients with PC and for the design of individually tailored treatments. The aim of this review was to provide an update of the latest advances in knowledge on the application of carbohydrates, proteins, cell-free nucleic acids, circulating tumor cells, metabolome compounds, exosomes, and platelets in blood as potential biomarkers for PC, focusing on their clinical relevance and potential for improving patient outcomes.

show abstract

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Cited by 97 publications

References 58 publications

Prognostic value of serum soluble ST2 in professional athletes (Valor pronóstico de ST2 soluble en suero en deportistas profesionales)

Prognostic value of serum soluble ST2 in professional athletes (Valor pronóstico de ST2 soluble en suero en deportistas profesionales)

Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases

Liquid biopsy approach to pancreatic cancer

Contact Info

Product

Resources

About